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Abstract Reduction of epithelial cell–cell adhesion via
the transcriptional repression of cadherins in combination
with the acquisition of mesenchymal properties are key
determinants of epithelial–mesenchymal transition (EMT).
EMT is associated with early stages of carcinogenesis, can-
cer invasion and recurrence. Furthermore, the tumor stroma
dictates EMT through intensive bidirectional communica-
tion. The pathological analysis of EMT signatures is criti-
cally, especially to determine the presence of cancer cells at
the resection margins of a tumor. When diVusion barriers
disappear, EMT markers may be detected in sera from can-
cer patients. The detection of EMT signatures is not only
important for diagnosis but can also be exploited to
enhance classical chemotherapy treatments. In conclusion,
further detailed understanding of the contextual cues and
molecular mediators that control EMT will be required in
order to develop diagnostic tools and small molecule inhi-
bitors with potential clinical implications.
Keywords Stroma · Cadherin · EMT · Metastasis · 
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Introduction
Epithelial–mesenchymal transition (EMT) is a type of plas-
ticity during which epithelial cells lose many of their epi-
thelial characteristics and acquire properties that are typical
of mesenchymal cells. Multiple terms, including epithelial–
mesenchymal transformation and transdiVerentiation have
been used to refer to EMT. To understand this, it is impor-
tant to review the terms epithelium and mesenchyme. An
epithelium is a sheet of cells that adhere laterally to each
other by cell-to-cell junctions. The epithelial layer is pola-
rized in such a way that bottom and top can be deWned as
basal and apical (inside and outside). The Wlamentous actin
cytoskeleton is apicobasally polarized and shows circum-
ferential organization. Cytokeratins are the main intermedi-
ate  Wlaments. The matrix-binding sites are on the basal
face, mediating adhesion mainly to the basal lamina pro-
tein, laminin. In contrast, mesenchymal cells form a diVuse
network with certain points on their surface adhering to
their neighbors. Actin Wlaments form a dense cortical net-
work of interacting Wbers, and perhaps trans-cytoplasmic
actin bundles. Vimentin is prominently expressed as an
O. De Wever (&) · M. Bracke
Laboratory of Experimental Cancer Research, 
Department of Radiotherapy and Nuclear Medicine, 




Department of Pathology, Ghent University Hospital, 
9000 Ghent, Belgium
B. De Craene · G. Berx (&)
Molecular and Cellular Oncology Unit, 
Department for Molecular Biomedical Research, VIB, 
Technologiepark 927, Zwijnaarde, 9052 Ghent, Belgium
e-mail: geert.berx@dmbr.ugent.be
B. De Craene · G. Berx
Department of Molecular Biology, Ghent University, 
9052 Ghent, Belgium
M. Sabbah · S. Emami · G. Redeuilh · C. Gespach
INSERM U 673, Paris, France
C. Gespach
Laboratory of Molecular and Clinical Oncology of Solid Tumors, 
Faculté de Médecine, Université Pierre et Marie Curie-Paris 6, 
755071 Paris Cedex 12, France482 Histochem Cell Biol (2008) 130:481–494
123
intermediate  Wlament. Contact sites to the extracellular
matrix (ECM) are widely distributed all around the cells.
The ECM forms a dense meshwork involving proteins like
collagens and Wbronectin. In contrast to epithelial cells,
mesenchymal cells also have a more extended and elon-
gated shape, and they have front-to-back leading edge
polarity (Tarin et al. 2005; Lee et al. 2006; Thiery and Sle-
eman 2006; Hugo et al. 2007; Berx et al. 2007). In clinical
practice pathologists use the terms “sarcomatous/sarcoma-
toid dediVerentiation” (i.e., “—resembling a sarcoma—”, a
malignant mesenchymal tumor) or anaplasia (meaning “—
to form backward—”) (Van Marck and Bracke 2005). EMT
is not considered a requisite for invasion and metastasis,
but compelling evidence shows that it can play an impor-
tant role in determining the dissemination of tumors (Berx
et al. 2007). In animal models, single non-dividing migra-
tory cells delaminate from primary tumors as evidenced by
powerful imaging techniques such as multiphoton micro-
scopy (Condeelis and Segall 2003). The characterization of
speciWc markers will undoubtedly help to identify the
nature and origin of all mesenchymal-like cells found in the
stroma and near the primary tumor.
Molecular and functional signatures of EMT
A key to EMT is the reduction of cell–cell adhesion by
transcriptional repression of cadherins (adherens junc-
tions), occludin and claudin (tight junctions), and desmo-
plakin (desmosomes) (Fig. 1). The Armadillo -catenin
protein is often lost from the cadherin-mediated cell–cell
contacts and shuttles to the nucleus to potentiate EMT sig-
naling events (Stemmer et al. 2008). Circumferential
F-actin Wbers of the cytoskeleton are replaced by a Rho-
mediated network of stress Wbers (occasionally positive for
the myoWbroblast marker -smooth muscle actin), at the tip
of which ECM adhesion molecules localize, including inte-
grins v6, fascin, and integrin linked kinase (ILK) (Bates
et al. 2005; Vignjevic et al. 2007; Fuchs et al. 2008). These
changes are suYcient for the cells to separate, lose apico-
basal polarity and gain a more spindle shape, all facilitating
cellular migration (Hugo et al. 2007; Lee et al. 2006).
However, cells produced by EMT are not always motile
and invasive. In Wbrotic kidney, Wbroblasts derived from
tubular epithelia do not migrate (Kalluri and Neilson 2003).
The expression of intermediate Wlaments is also changing
during EMT, with vimentin being typical of mesenchymal
cells and diVerent types of cytokeratin being characteristic
of epithelial cells. Matrix metalloproteases (MMP’s) such
as MMP-1, -2, -3, -7 and -14 are frequently upregulated
during EMT, potentially enabling cells to detach from each
other (via cadherin ectodomain shedding) and to penetrate
the basement membrane. ECM synthesis changes from
basal lamina proteins to interstitial forms including colla-
gen type I, Wbronectin, secreted protein acidic and rich in
cysteine (SPARC) and tenascin C (Nguyen et al. 2005).
Furthermore, matricellular proteins, which bridge the func-
tional and physical gap between ECM-associated proteins
and cell surface proteins, were recently implicated in the
EMT process. This is exempliWed by induction of EMT in
epithelial MCF-7 breast cancer cells by loss of the Wnt-
induced signaling protein (WISP)-2 (Fritah et al. 2008).
E-cadherin (epithelial cadherin) is essential for maintaining
epithelial integrity of many embryonic and adult tissues. It
has been known for a long time that the loss of epithelial
diVerentiation in carcinomas is linked to abnormal, tumor-
restricted reduction in the expression of E-cadherin (Semb
and Christofori 1998; Strumane et al. 2004). Multiple
mechanisms of E-cadherin loss have been described,
including abnormal proteolytic cleavage, loss of heterozy-
gosity and inactivating E-cadherin mutations, but lately the
mechanism of transcriptional silencing is acquiring much
attention. The loss of E-cadherin expression at the tran-
script level was Wrst identiWed in several human cancer cell
lines and later in diVerent human cancers, including pros-
tate, breast, colorectal and thyroid cancers (Reviewed in
Van Aken et al. 2001; Strumane et al. 2004). This initiated
the elaborate analysis of the mouse E-cadherin promoter,
which has been of primary importance in unraveling the
regulatory mechanisms of E-cadherin transcription. Analy-
sis of the mouse proximal E-cadherin promoter identiWed
E-box sequences that determine epithelium-speciWc expres-
sion (Behrens et al. 1991). Inactivation of these consensus
E-box sequences resulted in transcriptional activity of the
E-cadherin promoter in mesenchymal cells, which indi-
cated the existence of repressors that silence E-cadherin
expression in non-epithelial cells. A major breakthrough
was the identiWcation of a series of transcriptional repres-
sors, such as Snail, Slug, SIP1/ZEB2 (Smad Interacting
Protein)/(Zinc Wnger E-box Binding homeobox), deltaEF1/
ZEB1 and the basic helix-loop-helix (HLH) transcription
factor E47, which can directly bind the E-cadherin pro-
moter and repress E-cadherin transcription (Cano et al.
2000; Batlle et al. 2000; Comijn et al. 2001; Eger et al.
2005). Importantly, these E-cadherin repressors have been
linked to particular EMT processes during development
(Nieto 2002; Vandewalle et al. 2005; Van de Putte et al.
2003). Indeed, overexpression of these transcription factors
in epithelial cells not only results in loss of E-cadherin
expression but also reprograms the cells toward a mesen-
chymal cell state. During EMT, transcription factors that
reduce E-cadherin expression also downregulate other
adhesion molecules and induce mesenchymal features in a
coordinated manner (Cano et al. 2000; Vandewalle et al.
2005; De Craene et al. 2005; Aigner et al. 2007). Condi-
tional expression of Snail in DLD-1 colorectal cancer cellsHistochem Cell Biol (2008) 130:481–494 483
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induces invasion of elongated, solitary cells into collagen
type I gels (1 mg/ml) as evidenced by H&E stained paraYn
sections from 14 day cultures (Fig. 2). In the absence of
Snail expression DLD-1 cells form a monolayer on top of
collagen type I gels. Interestingly, it was recently shown
that knock-down of deltaEF1/ZEB1 in dediVerentiated
human epithelial colon and breast cancer cell lines results
in re-expression of E-cadherin and other epithelial diVeren-
tiation markers (Eger et al. 2005; Spaderna et al. 2006,
2008). In addition, to the above-described transcription fac-
tors, several other factors that induce EMT with typical loss
of E-cadherin expression have been identiWed, such as
TWIST, homeobox (HOX)-B7, CArG box-binding factor-
A (CBF-A), Mesenchyme Forkhead 1 (FOXC2), and Krüp-
pel-like factor (KLF)-8 (Venkov et al. 2007; Mani et al.
2007; Wu et al. 2006; Wang et al. 2007). Transrepression
of E-cadherin transcription is accompanied by the induc-
tion of N-cadherin (neural cadherin) or cadherin-11 expres-
sion. This so-called cadherin switch (Vandewalle et al.
2005) is believed to contribute to malignant cancer progres-
sion (Wheelock et al. 2008). The expression of these tran-
scription factors seems to be regulated by pathways known
to promote tumor progression, including transforming
growth factor (TGF)- , vascular endothelial growth factor
and scatter factor/hepatocyte growth factor (SF/HGF)
(reviewed in Peinado et al. 2007). For instance, TGF-
mediates EMT by signaling via receptor similar to mothers
against decapentaplegic (Smad)2/3 and through high-
mobility group AT-hook (HMGA)-2 family of nonhistone
chromatin proteins, the latter of which coordinates the
expression of both Snail and Slug and the basic HLH-tran-
scription factors Twist and Id2 (Thuault et al. 2006). Other
recently described important modulators of EMT are small
noncoding RNAs of 20- to 22-nucleotides (microRNAs,
miRNAs) that inhibit gene expression at the post-transcrip-
tional level: miR-141, miR-200b and miR-205 families
control expression of ZEB1 and ZEB2 (Park et al. 2008;
Gregory et al. 2008). ProWling miRNA expression of the
NCI60 panel of human cell lines which are used for drug
screening revealed that the miR-141 and miR-200b fami-
lies of miRNAs were striking markers of the epithelial phe-
notype. Selective knockdown of miR-141, miR-200b and
miR-205 family miRNAs was suYcient to reduce E-cad-
herin expression in a ZEB1/ZEB2-dependent way, leading
to increased cell motility and thus EMT in epithelial
MDCK3 and HCT116 cells. Conversely, ectopic expres-
sion of these miRNAs led to the re-expression of E-cad-
herin and epithelial phenotypes in MDCK cells that had
undergone EMT and in mesenchymal MDA-MB-231
breast cancer cells (Park et al. 2008; Gregory et al. 2008).
Each of the 400 miRNAs known to exist in mammalian
cells has multiple targets, making them powerful regulators
of complex processes such as diVerentiation and cancer
progression. Indeed, a strong link between miRNA and
human cancers has been established, as it has been demon-
strated that miRNAs act either as oncogenes (e.g., miR-
155, miR-17-5p and miR-21) (He et al. 2005; Voorhoeve
et al. 2006) or tumor suppressors (e.g., miR-15a, miR-16-1
and let-7) (Calin et al. 2002; Takamizawa et al. 2004; John-
son et al. 2007; Yanaihara et al. 2006).
Extracellular cues regulating EMT
Bi-directional communication between cancer cells and
their microenvironment, profoundly inXuences their beha-
vior and fate. Primary tumors are heterogenous and EMT is
observed particularly at the cancer invasion front, suggest-
ing the micro-environment as being essential in regulating
EMT. For example, melanoma cells that give rise to inva-
sive tumors when implanted into adult animals are repro-
grammed into a non-aggressive phenotype when implanted
into embryonic tissue (Hendrix et al. 2007). The stroma is
essential for tissue integrity and in cancer it drives tissue
invasion. MyoWbroblasts (also called cancer-associated
Wbroblasts) are important components of the tumor stroma
at the invasion front (De Wever and Mareel 2003; De
Wever et al. 2008). In squamous cervix and colon carcino-
mas, Snail expression is restricted to cancer cells near stro-
mal cells (Francí et al. 2006). Similarly, cancer cells
accumulating nuclear -catenin are distributed throughout
the tumor mass but particularly along the invasion front
(reviewed by Le et al. 2008). These results suggest that
myoWbroblasts docking at the invasion front regulate EMT
of nearby cancer cells. This myoWbroblast-induced EMT
may be caused by transient heterotypic cell–cell contacts or
by paracrine signals. In vitro, paracrine factors derived
from breast tumor myoWbroblasts induce EMT in PMC42-
LA breast cancer cells, with upregulation of vimentin, loss
of E-cadherin staining at cellular contacts and increased
nuclear -catenin signaling (Lebret et al. 2007). We previ-
ously demonstrated that tenascin C and SF/HGF produced
by myoWbroblasts provide convergent pro-invasive signal-
ing to colon cancer cells (De Wever et al. 2004; Denys
et al. 2008). ECM remodeling by myoWbroblasts is impli-
cated in progression of prostate cancer xenografts (Verona
et al.  2007). Furthermore, increased collagen production
and expression of 111 integrin in combination with
-SMA mediated contractility has a profound eVect on the
tumor stiVness that is linked with malignancy (Zhu et al.
2007). Matrix stiVness perturbs epithelial morphogenesis
by clustering integrins to enhance ILK activation and
increase Rho-kinase (ROCK)-generated contractility and
focal adhesions (Paszek et al. 2005; Hannigan et al. 2005).
Furthermore, engagement of collagen-binding integrins
promotes MMP-9-dependent shedding of the E-cadherin484 Histochem Cell Biol (2008) 130:481–494
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ectodomain in ovarian carcinoma cells (Symowicz et al.
2007). Another factor that is receiving considerable atten-
tion as an inducer of tumor metastasis is hypoxia (reduced
oxygen). There is a strong correlation between tumor
hypoxia on the one hand, and metastasis, poor prognosis
and patient mortality on the other. This hypoxic response is
mainly regulated by the hypoxia-inducible factor (HIF-1), a
basic HLH transcription factor composed of two subunits,
HIF-1 and HIF-1. The HIF-1 subunit is regulated by
oxygen tension, whereas HIF-1 is constitutively
expressed. In breast MCF-7 and ovarian SKOV-3 carci-
noma cell lines, Notch signaling is required to convert the
hypoxia stimulus into a Snail dependent EMT program
leading to increased motility and invasion (Sahlgren et al.
2008). Similarly, hypoxia or overexpression of HIF-1 pro-
motes EMT and metastatic phenotypes in human carcinoma
cells via direct induction of the E-cadherin repressor and
EMT inducer Twist by direct binding of HIF-1 at the
hypoxia response element in the TWIST proximal promoter
(Yang et al. 2008). Accordingly, E-cadherin levels were
down-regulated while vimentin and N-cadherin were
induced in these hypoxic cancer cells. Importantly, these
observations were extended in hypoxic human breast can-
cer cells showing cellular scattering, cell dissemination in
vivo, high vimentin levels, translocation of E-cadherin in
intracellular pools and nuclear translocation of the EMT
inducer Snail (Lester et al. 2007). Furthermore, co-expres-
sion of HIF-1 and TWIST in primary tumors of head and
neck cancer patients correlates with metastasis (Yang et al.
2008).
EMT signatures at early stages of carcinogenesis 
and cancer recurrence in vivo
Epidemiologic and clinical studies indicate that a strong
association exists between estrogen exposure and increased
breast cancer risk. Estrogen and/or estrogen metabolites
may act as procarcinogens through ER-—dependent or —
independent mechanisms, and may induce genotoxic eVects
to initiate breast, prostate or other cancers (Yager and
Davidson  2006; Huang et al. 2007). In support of these
Fig. 1 Schematic representation of EMT markers. Upregulated factors implicated in cytoskeletal changes and the mesenchymal phenotype (green
side) and repressed markers (red side) implicated in the maintenance of the epithelial phenotype. See text for more detailsHistochem Cell Biol (2008) 130:481–494 485
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observations, long-term treatment of spontaneously immor-
talized human breast epithelial cells by estradiol induced
several phenotypic traits characteristic of EMT, including
invasiveness, lower expression of the epithelial markers
E-cadherin, keratins, and induction of Snail, vimentin, and
the EMT inducer TGF- (Huang et al. 2007).
To identify early events associated with myc-induced
breast cancer, mouse mammary epithelial cells and stromal
cells were distinguished using Wbroblast speciWc protein
(FSP) and epithelial-speciWc whey acidic protein (WAP)
promoter driving transgenic expression of Cre recombinase
constructs in transgenic animals, respectively (Trimboli
et al. 2008). These two lineages were identiWed histologi-
cally by expression of the LacZ reporter gene from the
Rosa26LoxP locus. Of note, early EMT events occurred in
25–50% of myc-initiated breast cancer in WAP-myc; FSP-
cre; Rosa26LoxP mammary glands. The frequency of EMT
in tumor mice with the FSP-cre transgene was slightly
higher than in mice with the WAP-cre transgene, consistent
with the concept that Fsp-1 expression is an early event in
the EMT process. The MYC locus in the 131 patient sam-
ples was therefore analyzed for genome-wide LOH, using
the adjacent polymorphic marker D8S1128. Trimboli et al.
(2008) concluded that MYC ampliWcation is associated with
a predisposition of the epithelium to undergo EMT in
human breast cancer.
Early appearance of several molecular alterations char-
acteristic of EMT has been described in benign adenomas
of the multiple intestinal neoplasia (Min) mouse model of
familial adenomatous polyposis disease (Chen et al. 2008).
Inactivation of the adenomatous polyposis coli tumor sup-
pressor protein in this preclinical model recapitulates early
events underlying the progression of human colorectal can-
cer. A strong vimentin signal was observed in the cyto-
plasm of Min colonic neoplastic cells with characteristic
epithelial organization in 74 out of 79 tumors. Vimentin
staining was absent from the adjacent normal epithelium.
Microadenomas involving only three to Wve crypts in the
colon and small intestine displayed elevated vimentin
mRNA levels, suggesting that the classical EMT marker,
vimentin can be detected at an early stage of tumorigenesis.
Of note, Min mice on a tumor-resistant genetic background
have reduced tumor multiplicities, longer life-span, and
develop invasive intestinal tumors, that reached the submu-
cosa and muscle layers. In this model, immunohistochemis-
try demonstrated strong vimentin expression in the
epithelia of the primary tumor and in the neoplastic cells
invading the submucosa and muscular layers (Chen et al.
2008). Vimentin expression was not systematically distrib-
uted in all neoplastic cells, but was present in patches in
both central and peripheral tumor regions.
Breast cancer recurrence is an essential clinical manifes-
tation of tumor progression and represents the principal
cause of death from this disease. Using a conditional trans-
genic HER2/neu mouse model showing recurrence of
HER2/neu-induced mammary tumors, Moody et al. (2005)
demonstrated that the transcriptional repressor Snail is
spontaneously upregulated in recurrent tumors in vivo and
that recurrence is accompanied by EMT as evidenced by
spindle shaped morphology with downregulation of
Fig. 2 Conditional expression 
of Snail stimulates invasion. 
Light microscopy of H&E 
stained paraYn sections from 
doxycyclin-inducible 105 DLD-
1TR21-hSnailMyc/His colon 
cancer cells that were seeded on 
a layer of collagen type I (1 mg/
ml) in the absence (A and B) or 
presence (C and D) of doxycy-
clin; Wxation was after 14 days 
culture with medium refresh-
ments every 48 h. Arrows are 
invasive DLD-1 cells. Scale 
bar =5 0m486 Histochem Cell Biol (2008) 130:481–494
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cytokeratin and E-cadherin and upregulation of FSP. Fur-
thermore, Snail is suYcient to promote recurrence of mam-
mary tumors in vivo, and high levels of Snail are predictive
of shorter relapse-free survival in breast cancer patients.
Pathological signatures of EMT in tissue samples
Normal epithelial cells are incapable of invasion; they can
move laterally in the plane of the epithelium while retain-
ing adhesion to the underlying basement membrane.
Active movement in other directions appears to be forbid-
den to them. Such departures from the plane of an epithe-
lium depend on the acquisition of mesenchymal cell traits
(and on the shedding of some of their native epithelial
characteristics). As more mesenchymal traits are acquired,
it becomes more diYcult for the pathologist to distinguish
these cells from the true mesenchymal cells that surround
the neoplastic cells. This is especially important to deter-
mine the presence of cancer cells at the resection margins
of a tumor. Figure 3 shows an H&E staining of a basal cell
carcinoma with collective invading cancer cells and single
migratory cancer cells released from the tumor mass. The
analogy with mesenchymal Wbroblasts or myoWbroblasts
present in the ECM is striking. Immunohistochemistry can
help distinguish between cancer cells undergoing EMT and
stromal Wbroblasts, but it must be pointed out that most
cancer cells undergoing EMT partially shut down epithelial
markers while acquiring mesenchymal markers. Tradition-
ally, most studies have been done by looking at the expres-
sion of the intermediate Wlaments, cytokeratin and
vimentin. Routine immunohistochemistry employs a mix-
ture of two diVerent clones of monoclonal antibodies, AE1
and AE3 which cover most keratin subtypes (Goddard
et al. 1991). The emergence of vimentin in epithelial cells
of breast tumor correlates with a shorter post-operative sur-
vival of patients. Furthermore, the keratin/vimentin expres-
sion ratio is more predictive of a worse prognosis than
vimentin expression alone (Thomas et al. 1999). In cervical
cancer, vimentin expression is present in invasive carcino-
mas and in their lymph node metastases, but not in intra-
epithelial neoplasia precursor lesions (Gilles et al. 1996).
In villous human adenomas, which show high-grade dys-
plasia, the vimentin signals were negative in some sam-
ples, whereas others showed strong, patchy staining.
Expression of E-cadherin varied inversely with vimentin
expression independently of Snail and Twist. Conversely,
vimentin expression correlated with Wnt and TGF- sig-
naling and with reduced levels of the Ki-67 proliferation
marker (Chen et al. 2008). Cadherin switching may pro-
vide adhesion properties more suitable for a migrating cell.
Reduced E-cadherin expression and gain of N-cadherin
expression in cancer cells may be the result of EMT which
is very diYcult to detect in vivo. Double labeling of frozen
sections with speciWc E- and N-cadherin antibodies show
that invasive micropapilary carcinoma, which metastasize
easily to lymph nodes, contains cancer cells that are
positive for N-cadherin, E-cadherin or both (Agiostratidou
et al.  2007). In agreement with these Wndings, other
researchers have observed N-cadherin expression in breast,
colon, gastric, esophageal, pancreatic and prostate tumors
(reviewed in Van Aken et al. 2001). The immunohisto-
chemical staining reaction of -catenin in normal
epithelium and in most non-invasive carcinomas, is pre-
dominantly membranous, sometimes with faint cytoplas-
mic staining. In EMT, an aberrant expression can be seen,
with sole cytoplasmic and/or nuclear staining. This sup-
ports the notion that competition between diVerent cellular
partners for the cytoplasmic pool of -catenin inXuences its
Wnal incorporation either in cell adhesion or in signal trans-
duction mechanisms. Nuclear accumulation of -catenin is
observed in colorectal cancer cells distributed along the
invasion front but not in the tumor center (Hlubek et al.
2007). Furthermore, gene expression proWling revealed
overexpression of EMT genes at the invasion front such as
TWIST, FSP and tenascin C. Indeed, when -catenin is
released from the adherens junctions, it can enter the
nucleus and lead to a transcription of putative invasion
related genes. Another cadherin-binding protein, p120cate-
nin, shifts it localization from cell–cell junctions to the
cytoplasm and this correlates with colon cancer progres-
sion and patient survival (Bellovin et al. 2005). Recent
research has also documented the role of the Snail super-
family in mediating the loss of epithelial adhesion mole-
cules. Immunohistochemical positivity of nuclear Snail
correlates with increased vimentin and decreased E-cad-
herin expression in esophageal squamous cell carcinoma
(Usami et al. 2008). The diVerent repressors of E-cadherin
transcription have already been associated with progres-
sion of diVerent cancer types, e.g., breast (Cheng et al.
2001; Blanco et al. 2002; Moody et al. 2005; Yang et al.
2004; Martin et al, 2005) and gastric cancer (Rosivatz et al.
2002). Although the correlative expression data of the
diVerent E-cadherin repressors versus E-cadherin are over-
whelming, care should be taken with their interpretation
because many of these data are based on RT-PCR and on
the use of antibodies with undeWned speciWcity.
A large-scale tissue microarray-based immunohisto-
chemical study of 479 invasive breast carcinomas revealed
upregulation of mesenchymal markers (vimentin, -SMA,
N-cadherin and cadherin-11) and overexpression of pro-
teins involved in ECM remodeling and invasion (SPARC,
laminin and fascin), together with reduction of characteris-
tic epithelial markers (E-cadherin and cytokeratin) particu-
larly in breast tumors with the “basal-like phenotype”
(Sarrió et al., 2008). Gene expression analysis using cDNAHistochem Cell Biol (2008) 130:481–494 487
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Oncochip microarray of metastatic versus non-metastatic
melanomas identiWed diVerentially expressed genes impli-
cated in EMT. Validation of these expression data in an
independent series of melanomas using tissue microarrays
conWrmed that the expression of a set of proteins included
in the EMT group (N-cadherin, osteopontin and SPARC)
was signiWcantly associated with metastasis development
(Alonso et al. 2007). A similar oligonucleotide microarray
study on papillary thyroid carcinoma from central and inva-
sive regions and of normal thyroid tissue was performed.
The invasion fronts were consistently characterized by the
presence of mesenchymal markers and absence of epithelial
markers. Furthermore, immunohistochemical analysis
revealed that overexpression of vimentin associated with
papillary thyroid carcinoma cell invasion (Vasko et al.
2007). Molecular classiWcation of fresh-frozen and forma-
lin-Wxed head and neck squamous cell carcinomas showed
that genes involved in EMT are the most prominent mole-
cular characteristics of high-risk tumors (Chung et al.
2006). In conclusion, we strongly insist that the occurrence
of the EMT signature should be explored in large-scale
studies of human clinical tumors in order to predict their
metastatic potential.
Pathological signatures of EMT in biological Xuids
A number of molecules related to EMT can be assessed in
biological Xuids from cancer patients. Particularly in serum
they reXect either the pathogenesis or the consequences of
the phenomenon. Table 1 summarizes their applications in
diVerent types of cancer.
Scatter factor/hepatocyte growth factor concentrations in
serum are correlated with metastatic spread, they possess
prognostic value, and they are useful for monitoring ther-
apy. They can also be used as a urine parameter for diagno-
sis of transitional carcinoma of the bladder. Fibroblast
growth factor-2 (FGF-2), another tyrosine kinase receptor
ligand, is an endothelial-to-mesenchymal transformation
marker, its serum concentrations correlate with tumor
growth rate, volume, grading and staging. Its main clinical
usefulness, however, resides in monitoring the eVect of
angiogenesis inhibitors. In prostatic cancer an inverse cor-
relation between prostate-speciWc antigen (PSA) and FGF-
2 has repeatedly been observed (Usami et al. 2008). While
the EMT inducer TGF- as a circulating marker is diYcult
to interprete, the serum concentrations of its functional acti-
vators, MMP-9 and CD44 (mainly its spliced isoform v6),
have proven to possess prognostic information. Assessment
of the urine concentrations of MMP-9 was claimed to con-
tribute to the diagnosis of bladder cancer. Circulating tenas-
cin-C, a matricellular protein acting in concert with SF/
HGF, can discriminate between good and bad prognosis in
numerous cancers, and its cut-oV level was determined at
96 ng/ml. Tenascin-C serum concentrations also correlated
with the vascularization of the tumors. A central player in
cancer progression is p53, and this tumor suppressor’s level
in circulation was found to be higher in cancer patients than
in normal individuals. This is presumably the result of the
increased biological half-life of many p53 mutants. More-
over, mutations in exons 5 and 6 are particularly immuno-
genic, and elicit detectable auto-immune anti-p53
antibodies in the circulation (IgM and IgG). Although p53
and its antibodies were shown to correlate with prognosis
and therapeutic response of head- and neck cancer, their
major applicability is in epidemiological studies, where
mutagenic pressure from the environment has to be
assessed.
The switch from E- to N-cadherin is considered typical
for EMT, and enzymatically shed, soluble ectodomains
from both cadherins have been detected at elevated levels
in the serum of cancer patients reviewed in (De Wever
et al.  2007). Conceptually the measurement of soluble
E-cadherin (sE-cad) may be less straightforward, because
Fig. 3 Histology of basal cell carcinoma. Hematoxylin and eosin
staining of a basal cell carcinoma showing the collective invasion of
epithelial cancer cells into the extracellular matrix (arrows, panel A).
Single cancer cells detached from the tumor mass and showing traits of
epithelial–mesenchymal transition are indicated by arrows (panel B).
Stromal (myo)Wbroblasts are indicated by arrowheads.  Scale
bars =5 0m488 Histochem Cell Biol (2008) 130:481–494
123
E-cadherin is downregulated in carcinomas. Soluble N-
cadherin (sN-cad), however, may be a very sensitive cir-
culating marker, because it is upregulated in cancer cells
and in stromal myoWbroblasts. Two members of the kalli-
krein family, hK3 (or PSA) and hK4 (prostase) were
shown to induce EMT in prostatic carcinoma cells in vitro
(Lawrence et al. 2007), and both members are tumor
markers for prostatic carcinoma. PSA is not only useful
for the monitoring and follow up of therapy, it even con-
tributes to the diagnosis and staging of prostatic carci-
noma patients. Additional measurements have reWned the
interpretation of PSA values. These additional measure-
ments include the rate of the PSA increase (more or less
than 0.75 ng/ml or 20% a year), PSA density (serum PSA/
prostatic volume), age-related reference values, determi-
nation of free/complexed PSA in serum and neural net-
work assistance.
Loss of epithelial cell polarity and of junctional contacts
in cancer, in combination with basement membrane break-
down, removes the barriers for apical markers to diVuse
into the extracellular Xuids. Some high molecular weight
apical mucins, which normally circulate at extremely low
concentrations, are sensitive markers for loss of cell–cell
contact in cancer. Nowadays, they belong to the most fre-
quently prescribed tumor markers in clinical chemistry, and
are known as carcino-embryonic antigen (CEA), CA 15-3,
CA 19-9 and CA 125. As a result of cell–cell contact loss in
hepatocellular carcinoma, -fetoprotein (AFP) is upregu-
lated (Gleiberman et al. 1989), and has proven to be an
excellent serum marker for this type of cancer.
Table 1 Organ-related application of circulating EMT markers
References are a Rosen et al. 1997, b Sheen-Chen et al. 2005, c Dluzniewska et al. 2002, d Ren et al. 2005, e Chau et al. 2008, f Takigawa et al.
1997, g Tanaka et al. 2004, h Granato et al. 2004, i Sliutz et al. 1995, j George et al. 2002, k McMeekin et al. 2007, l Homer et al. 2002, m Dosquet
et al. 1997, n Ueno et al. 2001, o Le Page et al. 2006, p Meyer et al. 1995, q Vesely et al. 2004, r Nutt et al. 2003, s Somiari et al. 2006, t Patel et al.
2007, u Mihaylova et al. 2007, v Lein et al. 1997, w Li et al. 2008, x Kawano et al. 2005, y Stickeler et al. 2000, z Saito et al. 1998, aa Gazzaniga
et al. 2005, ab Takeda et al. 2007, ac Pauli et al. 2002, ad Ishiwata et al. 2005, ae Adzic et al. 2004; af Famulski et al. 2006, ag Attallah et al. 2003,
ah Segawa et al. 1997, ai Luo et al. 1994, aj Suwa et al. 1997, ak Kolomecki et al. 2005, al Gumus et al. 2004, am Müller et al. 2006, an Tang et al.
2001, ao Bergström et al. 2004, ap Murray et al. 2000, aq Bergqvist et al. 2004, ar Laurent-Puig et al. 1995, as Suzuki et al. 2004, at Derycke et al.
2006, au De Wever et al. 2007, av Shariat et al. 2005, aw Velikova et al. 1998, ax Charalabopoulos et al. 2006, ay Gadducci et al. 1999, az Kuefer
et al. 2005, ba Chan et al. 2005, bb Hautmann et al. 2000, bc Polascik et al. 1999, bd Obiezu and Diamandis 2005, be Bracke 2006, bf Chevinsky
1991, bg Thomson et al. 1969, bh Hilkens et al. 1987, bi Ritts Jr et al. 1984, bj Papantoniou et al. 2006, bk Abe et al. 1999, bl Molina et al. 1989,
bm Gadducci et al. 2004, bn Bast et al. 1998, bo Creaney et al. 2007, bp McIntire et al. 1975, bq Parikh et al. 2007, br Elgort et al. 1973
1 Assay on urine
2 Decreased concentrations indicate better prognosis
3 Also valid for CD44v5
4 Expressed by circulating cancer cells
Organ or tissue/
marker
SF/HGF FGF-2 MMP-9 CD44v6 Tenascin-C p53 Anti- p53 sN-cad sE-cad PSA hK4 CEA CA 15-3 CA 19-9 CA125 AFP
Bile ducts bf bi bp
Bladder a1 r1 va a 4 al av1 bf
Breast b h s w ae am at bb bf bh bj
Cervix i bf bk bn
Colorectum c j ab af an aw bg bi bp
Endometrium k bf bn
Esophagus d ag ao bf
Head and neck l t x ac bf
Kidney m bf bq
Liver e am bf bi bp
Lung (small cell) f ah ap bk
Lung (non-
small cell)
n2 ua d a i a q a x b f b k
Mesothelium bf bo
Ovary o y ay bd bf bm bn
Pancreas ar au bf bi bp
Prostate p aj as at az bc be bf
Stomach g z3 ba bf bi bp
Testis bf br
Thyroid q ak bfHistochem Cell Biol (2008) 130:481–494 489
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Does EMT aVect cancer treatment regimens?
Selective tyrosine kinase inhibitors are promising to treat
cancers driven by activated tyrosine kinases such as Bcr-Abl
in chronic myelogenous leukemia, c-Kit in gastrointestinal
stromal tumors and EGF receptor (EGFR) in non-small cell
lung cancer (NSCLC). GeWtinib (Iressa) and erlotinib (Tarc-
eva) are selective inhibitors of the EGFR receptor tyrosine
kinase and is currently used to treat NSCLC patients (Guo
et al. 2008). Although most NSCLC tumors express EGFR,
only a fraction of patients with tumors dependent on EGFR
for growth and survival respond clinically to EGFR inhibi-
tors. These tumors appear to contain EGFR-activating muta-
tions or have undergone ampliWcation of EGFR gene copy
number. Furthermore, a subset of non-small cell lung carci-
nomas that do not respond to erlotinib therapy have low lev-
els of E-cadherin and higher levels of mesenchymal type
transcripts such as vimentin and Wbronectin (Thomson et al.
2005). The bulk of Thomson’s evidence is derived from
NSCLC cell lines, but some conWrmatory evidence comes
from immunohistochemical staining of sections of human
tumors (Yauch et al. 2005). Furthermore, ILK-mediated
EMT predicts hepatocellular carcinoma sensitivity to
EGFR-targeted therapies (Fuchs et al. 2008).
Alternatively, many routine cancer treatments may stim-
ulate EMT and thus enhance invasion and metastasis.
Chronic chemotherapy with oxaliplatin (a third generation
platinum compound) induces EMT in colorectal cancer cell
lines (Yang et al. 2006). In another example, ionizing radia-
tion induces changes associated with EMT such as
increased migration, F-actin stress Wber formation, and dis-
turbed E-cadherin pattern in A549 lung epithelial cells in
vitro (Jung et al. 2007). Human malignant gliomas are
lethal neoplasms. Involved-Weld radiotherapy is the most
important therapeutic measure. Most relapses originate
from the close vicinity of the irradiated target Weld. Interest-
ingly, sublethal doses of irradiation enhance the migration
and invasiveness of human malignant glioma cell lines in
vitro. IR-induced migration is p53-independent, and
involves enhanced expression of v3 integrin, altered
MMP-2 and MMP-9 expression and activity proWles,
altered expression of membrane type 1 MMP and tissue
inhibitor of metalloproteinases-2, and altered BCL-2/BAX
balance favoring resistance to apoptosis (Wild-Bode et al.
2001). Current approaches to cancer treatment involving
more intensive radiotherapy regimens have been suggested
to be associated with a higher incidence of local or distant
metastasis (Jung et al. 2007). Therefore, a subset of patients
may beneWt from a combination of radiotherapy and EMT
inhibitors. We did not Wnd prospective randomized clinical
trials providing level 1 evidence in favor of or against such
side eVects of treatment so our discussion is admittedly
speculative.
Epithelial–mesenchymal transition signatures can be
exploited to enhance classical chemotherapy treatments.
Gain of N-cadherin expression is a typical example of the
EMT signature and it has been linked with drug resistance
(Zhang et al. 2007). Interestingly, ADH-1 (an N-cadherin
cyclic pentapeptide antagonist) sensitizes N-cadherin-
expressing melanoma cells to the anti-tumor activity of
melphalan in melanoma models (Mariotti et al. 2007;
Augustine et al. 2008). Recent work provides evidence to
support the possibility of exploiting EMT as a potential
therapeutic target in cancer (Sabbah et al. 2008).
Conclusion
Converging evidence using in vitro cell culture models,
transgenic mouse models, gene signature microarray analy-
sis and immunohistochemistry points out that EMT,
amongst other mechanisms, is implicated in early steps of
carcinogenesis, cancer cell invasion and metastasis and
recurrence. The list of molecular signatures deWning EMT
is growing and will eventually lead to a clear deWnition use-
ful for daily practice in pathology and clinical biology.
Understanding the molecular basis of EMT is essential for
designing small-molecule inhibitors targeting the EMT
response. These can be used to enhance classical chemo-
therapy treatments.
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